Nachammai K, Keerthi G S Nair, Ramaiyan Velmurugan, Sathesh Kumar S Pavithra K
Nachammai K, Keerthi G S Nair*, Ramaiyan Velmurugan, Sathesh Kumar S Pavithra K
Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, Chennai, India.
Volume - 13,
Issue - 11,
Year - 2020
Objectives: Drugs with shorter half-life administered to patients get easily cleared from the body, which makes frequent administration of the drugs necessary. This makes patient compliance an important factor that determines the efficiency of treatment. Sustained release of drugs on demand is still a challenge in the field of drug delivery that motivated us to work towards designing a simple system that can help to achieve a sustained release of drug from nanoparticles. Methods: Mefenamic acid and Mosapride were made into nanoparticles using hot homogenization technique and characterized. In-vitro drug release of conventional dosage form and nanoparticles were performed. Results: The Mefenamic acid and Mosapride nanoparticles obtained proved a Particle size of 180nm and 190nm respectively. Zeta potential was observed to be -25 mV and -28 mV. TEM proved that the nanoparticles were of spherical in shape. In-vitro drug release profile showed a significant drug release in nanoparticle when compared with the marketed formulation. Conclusion: These works contribute to improve Mefenamic acid and Mosapride clinical use, and further develop drug carriers for achieving sustained and controlled the release of the drugs in demand.
Cite this article:
Nachammai K, Keerthi G S Nair, Ramaiyan Velmurugan, Sathesh Kumar S Pavithra K. Sustained – Release study on Mefenamic acid and Mosapride loaded solid lipid Nanoparticles: In vitro Characterization. Research J. Pharm. and Tech. 2020; 13(11):5391-5395. doi: 10.5958/0974-360X.2020.00943.9
1. Alison H. Thomson. Introduction to Clinical Pharmacokinetics. Paed Perinatal Drug Ther 2000; 4:3-11.
2. Greenblatt DJ. Elimination Half-Life of Drugs: Value and Limitations. Ann Rev Med 1985; 36: 421-427.
3. Chivers, Sidney. Re: What happens during half lifes when there is only one atom left?". Mad Sci Network 2003.
4. Mifsud Janet. The clinical relevance of pharmacokinetics and drug interactions with anti-epileptic drugs. Journal of the Malta College of Pharmacy Practice.2009; 15:23-28.
5. Bhatia S. Nanoparticles types, classification, characterization, fabrication methods and drug delivery applications. In Natural Polymer Drug Delivery Systems. Springer, Cham.2016; 33-93.
6. Abhilash M. Potential applications of Nanoparticles. International Journal of Pharma and Bio Sciences 2010; 1: 1-5.
7. U.S. FDA/CDER, Guidance for Industry, Dissolution testing of immediate release solid oral dosage forms 1997.
8. Zhang H, Yu L. Dissolution Testing for Solid Oral Drug Products: Theoretical Considerations. American Pharmaceutical Review.2004; 7: 26-31.
9. Wang Q, Fotaki N, Mao Y. Bio relevant Dissolution: Methodology and Application in Drug Development”. Dissolution Technologies. 2009; 4: 6-12.
10. U.S. FDA/CDER, Guidance for Industry: Immediate release solid oral dosage forms, “Scale-up and post approval changes: chemistry, manufacturing, and controls, in vitro dissolution testing and in vivo bioequivalence documentation”, 1995.
11. Immediate Release Solid Oral Dosage Forms, Scale-Up and Post approval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation; Guidance for Industry; U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), U.S. Government Printing Office: Washington, DC, 1995.
12. Kumar, P.D., Subas, D.C., Subrata, C. and Soumen, R. Formulation and evaluation of solid lipid Nano particles of a poorly water-soluble model drug ibuprofen. International Research Journal of Pharmacy, 2012; 3:132-137.
13. Shumaia Parvin1, Md. Abu Shuaib Rafshanjani2, Md. Abdul Kader Parvin et al., International Current Pharmaceutical Journal. Formulation and evaluation of dexamethasone loaded stearic acid nanoparticles by hot homogenization method November 2014; 3: 331-335.
14. Lander R, Manger W, Scouloudis M, Ku A, Davis C, Lee A. Gaulin. homogenization: a mechanistic study. Biotechnology Prog. 2000; 16:80–5.
15. Jahnke S. The theory of high-pressure homogenization. In: Muller RH, Benita S, Bohm B, editors. Emulsions and Nano suspensions for the formulation of poorly soluble drugs. Stuttgart: Med pharm Scientific Publishers; 1998; 177–200.
16. S. Mukherjee, S. Ray, and R.S. Thakur Solid Lipid Nanoparticles: A Modern Formulation Approach in Drug Delivery System -Indian J Pharm Sci. 2009; 71: 349–358.
17. P. Ekambaram, a. Abdul Hasansathaliand K. Priyanka. Solid lipid nanoparticles: a review sci. Revs. Chem. Commun.: 2012; 2: 80-102.
18. Kuntsche, J, J.C. Horst, and H. Bunjes, Cryogenic transmission electron microscopy (cryo-TEM) for studying the morphology of colloidal drug delivery systems. International journal of pharmaceutics. 2011; 41:120-137.
19. W. Mehnert, K. Mader, Solid lipid nanoparticles production, characterization and applications. Advanced Drug Delivery Reviews 2001; 47: 165–196.
20. J. Liu, T. Gong, C.G. Wang, Z.R. Zhong. Solid lipid nanoparticles loaded with insulin by sodium cholate phosphatidylcholine-based mixed micelles: preparation and characterization, International Journal of Pharmaceutics 2007; 340:153–162.
21. MuÈller, R.H., K. MaÈder, and S. Gohla, Solid lipid nanoparticles (SLN) for controlled drug delivery–a review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics. 2000; 50: 161-177.
22. Hu, L., et al., Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles. AAPS Pharm Sci Tech 2010; 11:582-587.
23. Liu J et al., Solid lipid nanoparticles loaded with insulin by sodium cholate phosphatidylcholine-based mixed micelles: preparation and characterization. International Journal of Pharmaceutics 2007; 340:153-162.
24. Müller, R., C. Jacobs, and O. Kayser, Nano suspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Advanced drug delivery reviews 2001; 47:3-19.
25. S. Jeganath, A. Arunachalam, V. Ashlin Viji, K. Sheeja Devi, Jayachandran. D. L1, Krishnamoorthy M. Rao Jeganath S. Et al./ formulation and evaluation of ofloxacin nanoparticles by emulsion polymerization method International Journal of Biological & Pharmaceutical Research 2012; 3: 193-196.
26. Abazinge M, Jackson T, Yang Q. comparison of invitro and invivo release characteristics of sustained release ofloxacin drug delivery. PubMed.gov. 2000; 7:77-81.
27. Y.B. Huang, Y.H. Tsai, W.C. Yang, J.S. Chang, P.C. Wu, K. Takayama, Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation, European Journal of Pharmaceutics and Biopharmaceutics 2004; 4: 607–614.